Edition:
United Kingdom

Axovant Sciences Ltd (AXON.OQ)

AXON.OQ on NASDAQ Stock Exchange Global Select Market

5.27USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$5.27
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
394,308
52-wk High
$27.93
52-wk Low
$4.60

Latest Key Developments (Source: Significant Developments)

BRIEF-Axovant Sciences Submitted Final Protocol With Statistical Analysis Plan To FDA For Dementia With Lewy Bodies Study
Wednesday, 6 Dec 2017 

Corrects headline to say the final protocol was submitted for dementia with Lewy bodies study, not Parkinson's study:AXOVANT SCIENCES - SUBMITTED FINAL PROTOCOL WITH STATISTICAL ANALYSIS PLAN TO FDA DESIGNATES UNIFIED PARKINSON DISEASE RATING SCALE - PART III AS PRIMARY EFFICACY ENDPOINT.AXOVANT SCIENCES LTD SAYS SUBMITTED PROTOCOL THAT DESIGNATES ADAS-COG & CIBIC+ AS CO-SECONDARY ENDPOINTS FOR PHASE 2B HEADWAY STUDY - SEC FILING.  Full Article

Axovant announces second fiscal quarter results
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Axovant Sciences Ltd :Axovant announces second fiscal quarter financial results and corporate updates.Q2 loss per share $0.64.Q2 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.Axovant Sciences Ltd - ‍Axovant held cash of $235.4 million at september 30, 2017​.  Full Article

Axovant sciences says exploring nelotanserin as treatment for Rem sleep behavior disorder
Monday, 13 Feb 2017 

Axovant Sciences Ltd : Axovant sciences announces preliminary results from interim analysis of phase 2 study testing investigational drug nelotanserin in Lewy body dementia patients . Axovant expects to initiate phase 3 program in second half of 2017 . Plans to expand study recruitment to further explore updrs findings and expects final results in mid-2017 . Axovant Sciences-in interim analysis, secondary endpoints did not demonstrate statistically significant differences for nelotanserin relative to placebo .Axovant Sciences-is exploring nelotanserin as a potential treatment for rem sleep behavior disorder (RBD) in patients with dementia with Lewy bodies.  Full Article

Axovant Sciences receives FDA fast-track designation for intepirdine
Monday, 26 Sep 2016 

Axovant Sciences Ltd :Axovant Sciences receives FDA fast-track designation for intepirdine as an investigational treatment for dementia with lewy bodies.  Full Article

Axovant Sciences posts Q1 loss per share of $0.38
Monday, 15 Aug 2016 

Axovant Sciences Ltd : Axovant sciences announces expansion of dementia pipeline and reports financial results for the first fiscal quarter ended June 30, 2016 . Q1 loss per share $0.38 . Q1 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S . Axovant says Axovant and QAAM Pharmaceuticals (QAAM) have entered into an exclusive license agreement . Axovant says financial terms of transaction were not disclosed . Axovant plans to initiate clinical studies for RVT-103 shortly, with initial results expected in 2017 . Announces plan to develop RVT-103, a combination of Glycopyrrolate and Donepezil, as a potential treatment for patients with dementia .Axovant sciences ltd says axovant does not expect program to have a material effect on its use of cash in fiscal year ending March 31, 2017.  Full Article

Axovant Q4 loss per share $0.30
Monday, 6 Jun 2016 

Axovant Sciences : Q4 loss per share $0.30 .Q4 earnings per share view $-0.30 -- Thomson Reuters I/B/E/S.  Full Article

CORRECTED-BRIEF-Axovant Sciences Submitted Final Protocol With Statistical Analysis Plan To FDA For Dementia With Lewy Bodies Study

* AXOVANT SCIENCES - SUBMITTED FINAL PROTOCOL WITH STATISTICAL ANALYSIS PLAN TO FDA DESIGNATES UNIFIED PARKINSON DISEASE RATING SCALE - PART III AS PRIMARY EFFICACY ENDPOINT